NCT02678572Phase 3Completed

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Study sponsor: Delcath Systems Inc. · DCTH

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-05-18Actual

Enrollment · participants102Actual

Source updated2026-09-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-10 · 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Objective Response Rate (ORR) as determined by Independent Central Review Committee

+ Updated value

measure: Objective Response Rate (ORR) as Determined by Independent Central Review Committee.

The saved outcome text may be shortened. Check the source for full wording.

Check registry source

Study details

Conditions studied

Ocular Melanoma; Uveal Melanoma

Treatments or interventions studied

Not recorded

Primary outcomes · main study measures

Read the study measures

measure: Objective Response Rate (ORR) as Determined by Independent Central Review Committee.; description: Objective Response Rate (partial or complete) as determined by Independent Central Review Committee. This is assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR; timeFrame: Patients will be assessed for ORR from baseline through completion of treatment. [assessed up to 36 months].

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history